Friday, 25 September 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 19, 2026

The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond

View original at nasdaq.com
The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond Key Points AbbVie provides an attractive combination of income, value, and growth…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Enbridge has visible growth through the end of the decade, with roughly $50 billion of opportunities identified

    60% confidence

  • Realty Income has particularly promising opportunities in Europe, where the total addressable market is $8.5 trillion and competition is limited

    60% confidence

  • AbbVie should deliver solid growth over the next few years driven by drugs like Rinvoq and Skyrizi and promising late-stage pipeline programs

    60% confidence

  • The 10 stocks identified by Stock Advisor could produce monster returns in the coming years

    60% confidence

  • Now is a great time to invest in dividend stocks with above-average yields

    60% confidence

  • Enbridge expects to deliver growth across all aspects of its business, especially in natural gas transmission

    60% confidence

  • The Federal Reserve is virtually paralyzed by uncertainty about inflation and the job market

    60% confidence

Data points we hold from this source

S&P 500 · healthcare sector forward pe ratio17.4 ratio
S&P 500 · forward pe ratio20 ratio
AbbVie Inc. · dividend increase streak53 years
AbbVie Inc. · forward pe ratio14.3 ratio
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond — Source | Via News | ViaNews EU